Leadership Overview
Veristat has 4 executives leading key functions including strategy, finance, and operations.
Driven by scientific rigor, Veristat is dedicated to advancing clinical research and regulatory submissions, impacting pharmaceutical, biotechnology, and medical device development.
Driven by scientific rigor, Veristat is dedicated to advancing clinical research and regulatory submissions, impacting pharmaceutical, biotechnology, and medical device development.
Leadership Roles at Veristat
Kim McLean Boericke - Chief Executive Officer
Kim McLean Boericke, the Chief Executive Officer at Veristat, directs the company's overarching strategy and operational execution. Boericke guides the organization's mission to support pharmaceutical, biotechnology, and medical device companies through complex clinical trials and regulatory submissions. This leadership involves fostering a science-focused culture that prioritizes data integrity and patient outcomes. Boericke ensures Veristat's services align with industry advancements and client needs, driving the company's growth and market position. The Chief Executive Officer's focus remains on enhancing Veristat's capabilities to deliver critical insights and accelerate drug development timelines. Kim McLean Boericke's strategic vision shapes the company's direction, ensuring continued innovation and client success in a dynamic global landscape.
David Koster - Co-Founder & Chief Executive Officer
David Koster, the Co-Founder & Chief Executive Officer at Veristat, spearheads the company's strategic vision and foundational principles. Koster's leadership is integral to Veristat's identity as a science-focused clinical research organization, emphasizing a commitment to supporting pharmaceutical, biotechnology, and medical device clients. This role involves shaping the company's long-term objectives and ensuring its continued evolution in the research landscape. David Koster's influence extends to fostering partnerships and driving initiatives that enhance Veristat's service offerings. The Co-Founder & Chief Executive Officer's dedication to scientific integrity and client success underpins the organization's operational framework. Through strategic guidance, Koster ensures Veristat remains at the forefront of clinical trial support and regulatory submission expertise.
Joshua Korth - Chief Financial Officer
Joshua Korth, the Chief Financial Officer at Veristat, manages the company's financial health and strategic fiscal planning. Korth oversees all financial operations, including budgeting, forecasting, and resource allocation, ensuring robust financial infrastructure to support Veristat's growth as a full-service clinical research organization. This leadership position involves optimizing financial performance and driving profitability while maintaining compliance with industry standards. Joshua Korth's responsibilities extend to managing investments and financial risk, crucial for supporting pharmaceutical, biotechnology, and medical device clients through their clinical trials and regulatory submissions. The Chief Financial Officer's strategic financial insights enable informed decision-making across all departments. By ensuring financial stability, Joshua Korth directly contributes to Veristat's capacity for innovation and sustained client support.
John Balser - Founder & President & Statistical Chief & Officer
John Balser, the Founder & President & Statistical Chief & Officer at Veristat, establishes the company's core scientific and operational direction. Balser's multifaceted role encompasses leadership in statistical analysis, a critical component for supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology, and medical device companies. This position involves driving innovation in data interpretation and ensuring the highest standards of scientific rigor across all projects. John Balser's influence as President guides the overall organizational strategy and operational efficiency. The Founder & President & Statistical Chief & Officer's deep expertise in statistical methodologies underpins Veristat's reputation for scientific excellence. Through this leadership, John Balser ensures the company consistently delivers high-quality, data-driven insights that advance client research and development efforts.
Explore Leadership Teams in Business Services
Founded in 1949, Sandia National Laboratories, managed and operated by the National Technology and Engineering Solutions of Sandia, is one of three National Nuclear Security Administration research and development laboratories in the United States. They are headquartered in Albuquerque, New Mexico.
Company Leadership
CH
JP
TT
Cytek Biosciences is a leading cell analysis solutions company founded in 1992 and headquartered in Fremont, California with global offices across North America, Europe, and Asia. The company specializes in research and development of advanced cell analysis tools through its patented Full Spectrum Profiling technology. Cytek's product portfolio includes scientific instruments such as the Aurora and Northern Lights systems, cell sorters, reagents, and supporting software that enable high-resolution and high-sensitivity cell analysis for research purposes. The company provides comprehensive solutions for scientific research institutions and laboratories, with its Northern Lights CLC system available for clinical use in China and the European Union. Cytek Biosciences operates in the biotechnology and scientific research services sector, offering both business-to-business and business-to-consumer products through its website cytekbio.com and other distribution channels.
Company Leadership
MY
The Aurum Institute is a leading health impact organization focused on generating evidence for policy and translating it into practice. They specialize in clinical and implementation research, particularly in areas such as tuberculosis, HIV, and health systems strengthening. Their services include major development intervention programs and technical assistance aimed at improving health outcomes. The organization targets clients in Africa and globally, working to address pressing health challenges through innovative and integrated approaches.
Company Leadership GC
MM
VE
PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing their proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide.
Company Leadership KK
KK
KM
Frequently Asked Questions Regarding Veristat Top Executives and Leadership Team
Unlock more people and company data
